Allero Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 5

Employees

  • Latest Deal Type
  • M&A

  • Investors
  • 2

Allero Therapeutics General Information

Description

Developer of immunotherapies intended for immune-mediated disorders. The company offers non-invasive, patient-friendly treatments designed to induce long-lasting antigen-specific immune tolerance for conditions such as autoimmune diseases, allergic diseases and anti-drug antibodies.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • Erasmus MC Incubator
  • Marconistraat 16
  • 3029 AK Rotterdam
  • Netherlands
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Laboratorios LETI
Vertical(s)
Corporate Office
  • Erasmus MC Incubator
  • Marconistraat 16
  • 3029 AK Rotterdam
  • Netherlands

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Allero Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 16-May-2022 Completed Generating Revenue
3. Grant 16-Dec-2021 Completed Pre-Clinical Trials
2. Seed Round 03-Oct-2019 Completed Pre-Clinical Trials
1. Grant 01-Sep-2018 $57.7K Completed Pre-Clinical Trials
To view Allero Therapeutics’s complete valuation and funding history, request access »

Allero Therapeutics Patents

Allero Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4678183-A1 Treatment of immune diseases by administration of mrna formulations Pending 12-Jul-2024
WO-2021198220-A1 Treatment and prevention of secondary inflammation in patients suffering from a viral infection Inactive 30-Mar-2020
CA-3080253-A1 Treatment of immune diseases by administration of antigen-specific formulations Pending 25-Oct-2017
EP-3700552-A1 Treatment of immune diseases by administration of antigen-specific formulations Pending 25-Oct-2017
JP-2023159058-A Treatment of immune diseases by administration of antigen-specific formulations Active 25-Oct-2017 A61K39/35
To view Allero Therapeutics’s complete patent history, request access »

Allero Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Allero Therapeutics Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Curie Capital Venture Capital Minority
Swanbridge Capital Venture Capital Minority
To view Allero Therapeutics’s complete investors history, request access »

Allero Therapeutics FAQs

  • When was Allero Therapeutics founded?

    Allero Therapeutics was founded in 2016.

  • Where is Allero Therapeutics headquartered?

    Allero Therapeutics is headquartered in Rotterdam, Netherlands.

  • What is the size of Allero Therapeutics?

    Allero Therapeutics has 5 total employees.

  • What industry is Allero Therapeutics in?

    Allero Therapeutics’s primary industry is Drug Discovery.

  • Is Allero Therapeutics a private or public company?

    Allero Therapeutics is a Private company.

  • What is Allero Therapeutics’s current revenue?

    The current revenue for Allero Therapeutics is .

  • Who are Allero Therapeutics’s investors?

    Curie Capital and Swanbridge Capital have invested in Allero Therapeutics.

  • When was Allero Therapeutics acquired?

    Allero Therapeutics was acquired on 16-May-2022.

  • Who acquired Allero Therapeutics?

    Allero Therapeutics was acquired by Laboratorios LETI.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process